Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Valérie Izard"'
Autor:
Gilles Vassal, Carole Neves, Olivier Arnaud, Yannick Pletan, Olivier Amedee-Manesme, Zeina Antoun, Antoine Audry, Alexandra Auffret, Olivier Blin, Antoine Bril, Pierre Braquet, Soizic Courcier, Cécile Delval, Jacques Demotes Mainard, Isabelle Diaz, Elisabeth Fery Lemonier, Isabelle Giri, Valérie Izard, Valéry Labonne, Olivier Louvet, Isabelle Pelletier Bressac, Sophie Ravoire, Pierre Schiavi, Daniel Vasmant
Publikováno v:
Therapies. 66:301-307
Resume L’objectif de la Table Ronde etait d’aborder la Recherche Pre-competitive pour la premiere fois lors des Rencontres de Giens. Les participants venaient de l’industrie du medicament, des biotech, de l’industrie du dispositif, de l’aca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01c42e39babd69d3ab02f46f7719721f
https://doi.org/10.2515/therapie/2011049
https://doi.org/10.2515/therapie/2011049
Autor:
Valérie Izard, Gilles Bouvenot, Laurent Degos, Bertrand Xerri, Bruno Falissard, François Meyer
Publikováno v:
International Journal of Technology Assessment in Health Care. 26:124-130
Objectives: Post-listing assessment of pharmaceuticals depends on national habits. In England, the assessment is based on estimates of cost per quality-adjusted life-year. These are made some considerable time after listing (negative list). In France
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::828fe57d3e7e9645c15359f0c6c1bb5d
https://doi.org/10.1017/s0266462309990821
https://doi.org/10.1017/s0266462309990821
Autor:
Bruno Falissard, Myriam Zylberman, Michel Cucherat, Valérie Izard, François Meyer, Alexandre Barna, Frédéric De Bels, Rima de Sahb, Jean Delonca, Pascale Jolliet, Jean-Michel Joubert, Robert Launois, Claire Le Jeunne, Michel Lièvre, Florence Mahlberg Gaudin, Aurélie Moser, Patricia Perles, Martine Pigeon, Cécile Rey Coquais, Nadine Weisslinger, Bertrand Xerri
Publikováno v:
Therapies. 64:225-228
Resume Les donnees cliniques soumises au Comite des Medicaments a Usage Humain (CHMP) pour autorisation de mise sur le marche manquent frequemment de comparaisons directes pertinentes des produits. Ces comparaisons peuvent permettre aux autorites nat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84973715180c2b0063aa8363b5f46ed4
https://doi.org/10.2515/therapie/2009031
https://doi.org/10.2515/therapie/2009031
Autor:
Bruno Falissard, Myriam Zylberman, Michel Cucherat, Valérie Izard, François Meyer, Alexandre Barna, Frédéric De Bels, Rima de Sahb, Jean Delonca, Pascale Jolliet, Jean-Michel Joubert, Robert Launois, Claire Le Jeunne, Michel Lièvre, Florence Mahlberg Gaudin, Aurélie Moser, Patricia Perles, Martine Pigeon, Cécile Rey Coquais, Nadine Weisslinger, Bertrand Xerri
Publikováno v:
Therapies. 64:229-232
Frequently, in data packages submitted for Marketing Approval to the CHMP, there is a lack of relevant head-to- head comparisons of medicinal products that could enable national authorities responsible for the approval of reimbursement to assess the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::936ab420b52a4ef90b968ac19447e5d1
https://doi.org/10.2515/therapie/2009032
https://doi.org/10.2515/therapie/2009032